Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Pharmacoepidemiology and Drug Safety

• Publication date

  2016-05-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pds.4034PMID 27229855
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.

  2015cited by this paper
• Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation

  2015cited by this paper
• Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation

  2014cited by this paper
• The Danish Civil Registration System as a tool in epidemiology

  2014cited by this paper
• Anticoagulant-related gastrointestinal bleeding—could this facilitate early detection of benign or malignant gastrointestinal lesions?

  2014cited by this paper
• Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients

  2014cited by this paper
• Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.

  2014cited by this paper
• A very happy new year 2014 from Thrombosis and Haemostasis!

  2014cited by this paper
• Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.

  2014cited by this paper
• Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.

  2013cited by this paper
• New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis.

  2013cited by this paper
• Investigating differences in treatment effect estimates between propensity score matching and weighting: a demonstration using STAR*D trial data

  2013cited by this paper
• Interpreting the quality of health care database studies on the comparative effectiveness of oral anticoagulants in routine care

  2013cited by this paper
• A tutorial on propensity score estimation for multiple treatments using generalized boosted models

  2013cited by this paper
• Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

  2012cited by this paper
• The Danish National Prescription Registry

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples.

  2011cited by this paper
• The Danish National Patient Register

  2011cited by this paper
• A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

  2010cited by this paper
• Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study.

  2010cited by this paper
• High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data

  2009cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper
• Indications for propensity scores and review of their use in pharmacoepidemiology.

  2006cited by this paper
• Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin

  2004cited by this paper
• Evaluating medication effects outside of clinical trials: new-user designs.

  2003cited by this paper
• AMERICAN JOURNAL OF EPIDEMIOLOGY

  1965cited by this paper

• Safety and effectiveness of Rivaroxaban, Dabigatran and Apixaban in patients with non-valvular atrial fibrillation for stroke prophylaxis

  2025cites this paper
• Retrospective analysis of gastrointestinal bleedings with direct oral anticoagulants reported to EudraVigilance

  2023cites this paper
• Comparison of the Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients with or Susceptible to Thromboembolic Events

  2023cites this paper
• A review of the use of propensity score methods with multiple treatment groups in the general internal medicine literature

  2023cites this paper
• Comparison of Safety and Efficacy Between Dabigatran and Rivaroxaban in Nonvalvular Atrial Fibrillation in Tertiary Level Hospital

  2022cites this paper
• Propensity score methods for comparative-effectiveness analysis: A case study of direct oral anticoagulants in the atrial fibrillation population

  2022cites this paper
• Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real‐world analysis

  2022cites this paper
• Assessing Medicines for Use in the Geriatric Population

  2022cites this paper
• Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study

  2022cites this paper
• Secondary prevention of thrombosis with direct oral anticoagulants for hereditary hematogenous thrombophilia

  2021cites this paper
• Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy

  2021cites this paper
• Comparative Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients

  2021cites this paper
• Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a network metanalysis on 605,771 patients.

  2021cites this paper
• Critical appraisal and issues regarding generalisability of comparative effectiveness studies of NOACs in atrial fibrillation and their relation to clinical trial data: a systematic review

  2021cites this paper
• Comparison of non‐vitamin K antagonist oral anticoagulants on bleeding and thrombosis

  2021cites this paper
• Standard- vs. low-dose rivaroxaban in patients with atrial fibrillation: a systematic review and meta-analysis

  2021cites this paper
• An emulated target trial analysis based on Medicare data suggested non-inferiority of Dabigatran versus Rivaroxaban.

  2021cites this paper
• Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population‐based cohort studies

  2021cites this paper
• Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.

  2021cites this paper
• Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis

  2021cites this paper
• Improvement in age- and sex-dependent mortality in patients with atrial fibrillation between 2011 and 2016 – a nationwide retrospective study from Hungary

  2021cites this paper
• Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis

  2021cites this paper
• Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies

  2020cites this paper
• Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants-a Systematic Review and Meta-analysis.

  2020cites this paper
• Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation

  2020cites this paper
• The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: A real-world data cohort study

  2020cites this paper
• Different Risk Profiles of European Patients Using Direct Oral Anticoagulants or Vitamin K Antagonists: a Rapid Review

  2020cites this paper
• Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method

  2020cites this paper
• COMPARATIVE CHARACTERISTICS OF ANTICOAGULANTS AT ATRIAL FIBRILLATION IN COMORBID PATIENTS

  2020cites this paper
• Clinical use of direct oral anticoagulants in modern practice. Efficiency and safety

  2020cites this paper
• Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation

  2019cites this paper
• Safety of direct oral anticoagulants in real–world clinical practice: translating the trials to everyday clinical management

  2019cites this paper
• Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation

  2019cites this paper
• Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists

  2019cites this paper
• Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation.

  2019cites this paper
• Direct Comparison of Low-Dose Dabigatran and Rivaroxaban for Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation.

  2019cites this paper
• Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies

  2019cites this paper
• Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.

  2019cites this paper
• The use and adherence of oral anticoagulants in Primary Healthcare in Catalunya: a real-world data cohort study

  2019cites this paper
• Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study

  2019cites this paper
• Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland

  2018cites this paper
• Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update

  2018cites this paper
• Stroke prevention in atrial fibrillation : update with NOAC treatment and the impact of reversal

  2018cites this paper
• Réunion de concertation pluridisciplinaire a propos de l’anticoagulation du sujet âgé en fibrillation atriale : état des lieux après deux ans de fonctionnement

  2018cites this paper
• VARNOST IN UČINKOVITOST NOVIH ANTIKOAGULACIJSKIH ZDRAVIL PRI BOLNIKIH Z ATRIJSKO FIBRILACIJO – PROSPEKTIVNA KLINIČNA RAZISKAVA

  2018cites this paper
• Effectiveness and Safety of Non–Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation

  2018cites this paper
• Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review

  2018cites this paper
• Role of Hypertension and Other Clinical Variables in Prognostication of Patients Presenting to the Emergency Department With Major Bleeding Events

  2018cites this paper
• Dabigatran, Rivaroxaban, and Warfarin in the Oldest Adults with Atrial Fibrillation in Taiwan

  2018cites this paper
• Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation.

  2018cites this paper
• Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies

  2018influential citation
• Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.

  2018influential citation
• Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation.

  2018cites this paper
• Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study

  2018cites this paper
• Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study

  2018influential citation
• Aalborg Universitet Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation

  2017cites this paper
• Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants

  2017cites this paper
• Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients

  2017cites this paper
• Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis

  2017influential citation
• Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study

  2017cites this paper
• Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation

  2017influential citation
• Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban

  2017cites this paper
• The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation

  2017cites this paper
• Liver injury with direct-acting anticoagulants: has the fog cleared?

  2017cites this paper
• Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.

  2017cites this paper
• Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation

  2017cites this paper
• Oral anticoagulation and stroke risk

  2017cites this paper
• Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.

  2017cites this paper
• Descripción de las características clínicas y los factores predictores de eventos clínicos en pacientes que inician tratamiento con anticoagulantes orales directos

  2017cites this paper
• Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation

  2017cites this paper
• Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis

  2017cites this paper
• Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients

  2017cites this paper
• Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis

  2017cites this paper
• СНИЖЕНИЕ РИСКА СЕРДЕЧНО-СОСУДИСТОЙ СМЕРТНОСТИ И ИНСУЛЬТА У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ

  2016cites this paper
• Place and significance of observational studies of NOACs in patients with non-valvular atrial fibrillation from the standpoint of evidence-based medicine

  2016cites this paper
• Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

  2016cites this paper